Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-7-[4-[2-(2-Methylphenyl)Acetyl]-1-Piperazinyl]-4-Oxo- is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound is critical for the synthesis of novel fluoroquinolone antibiotics, offering a key building block for research and development in antimicrobial therapies. It is primarily required by pharmaceutical R&D laboratories, fine chemical manufacturers, and academic institutions focused on medicinal chemistry and new drug discovery.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of next-generation fluoroquinolone antibiotic candidates.
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies to develop new antimicrobial agents with improved efficacy and safety profiles.
• Active Pharmaceutical Ingredient (API) Development: Serves as a precursor in the multi-step synthesis of complex API molecules targeting bacterial infections.
• Fine Chemical Synthesis: Employed in custom synthesis and contract manufacturing for specialized chemical libraries and proprietary compounds.
• Biochemical Research: Potential tool compound for studying bacterial DNA gyrase and topoisomerase IV inhibition mechanisms.

Basic Information

Item	Details
Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-7-[4-[2-(2-Methylphenyl)Acetyl]-1-Piperazinyl]-4-Oxo-
CAS No.	1054047-84-5
Molecular Formula	C25H24FN3O4
Molecular Weight	449.48 g/mol
Synonyms	1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[4-[2-(2-methylphenyl)acetyl]-1-piperazinyl]-4-oxo-3-quinolinecarboxylic acid; 7-[4-(2-o-Methylphenylacetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Garenoxacin Intermediate; Garenoxacin Related Compound; AM-1155 Intermediate; T-3811 Intermediate; BMS-284756 Intermediate
EINECS	Contact for details

Quality Control

Every batch of this advanced intermediate is produced under strict quality management systems to ensure consistency and traceability. We provide comprehensive Certificates of Analysis (COA) detailing purity, identity, and impurity profiles, supported by analytical techniques including HPLC, NMR, and MS. Our quality commitment aligns with cGMP principles for pharmaceutical starting materials, ensuring reliability for critical R&D and scale-up processes.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (typically 15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.